HK Grey Market | Micot Pharmaceutical Surges 65%; Seer Tech Jumps 10%

Tiger Newspress06-23 16:15

Micot Pharmaceutical sharessurged 64.8% in Hong Kong’s grey market trading.

Micot Pharmaceutical is a Chinese biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for metabolic diseases, as well as cardiovascular and cerebrovascular diseases. Micot Pharma plans to list H shares on the Hong Kong Stock Exchange Main Board on June 24, 2026.

Its Core Product, MT1013, is a self-developed Phase III-stage dual-targeting receptor agonist polypeptide mainly designed to treat chronic kidney disease-secondary hyperparathyroidism.

Seer Tech shares jumped 9.5% in Hong Kong’s grey market trading.

Seer Tech is a Chinese intelligent robotics company specializing in proprietary robotic control systems, robot controllers, software, robots and related accessories. Seer Tech plans to list on the Hong Kong Stock Exchange on June 24, 2026.

Seer’s robotic control systems serve as the “robot brain,” supporting perception, positioning, decision-making, motion control, scheduling and optimization across robot fleets. The company develops and sells robots, controllers, software and accessories for use in industrial automation and other real-world applications. It has a customer base of more than 2,000 integrators and end customers across over 35 countries and regions, with products deployed in more than 20 sectors including 3C, automotive, new energy, semiconductors, construction machinery and biopharmaceuticals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment